BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND SMARCA4, hSNF2b, 6597, P51532, BRG1, SNF2L4, SNF2, SWI2, FLJ39786, BAF190, SNF2LB, SNF2-BETA, ENSG00000127616
231 results:

  • 1. Redox
    Wei XW; Lu C; Zhang YC; Fan X; Xu CR; Chen ZH; Wang F; Yang XR; Deng JY; Yang MY; Gou Q; Mei SQ; Luo WC; Zhong RW; Zhong WZ; Yang JJ; Zhang XC; Tu HY; Wu YL; Zhou Q
    Oncoimmunology; 2024; 13(1):2340154. PubMed ID: 38601319
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. [Clinical characteristics and prognosis analysis of 17 cases of smarca4-deficient chest tumors].
    Cao XN; Li Z; Wang QY
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Apr; 47(4):325-331. PubMed ID: 38599807
    [No Abstract]    [Full Text] [Related]  

  • 3. Treatment of Thoracic smarca4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go.
    Longo V; Catino A; Montrone M; Montagna ES; Pesola F; Marech I; Pizzutilo P; Nardone A; Perrone A; Gesualdo M; Galetta D
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542211
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. All That Is Small Is Not a Small-Cell Carcinoma: Thoracic smarca4-Deficient Undifferentiated Tumors Masquerading as SCLC.
    Rekhtman N
    Clin Cancer Res; 2024 May; 30(9):1708-1711. PubMed ID: 38416596
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Efficacy of immune checkpoint inhibitors in smarca4-deficient and TP53 mutant undifferentiated lung cancer.
    Chen J; Zheng Q; Wang J; Zhang X; Lv Y
    Medicine (Baltimore); 2024 Feb; 103(8):e36959. PubMed ID: 38394494
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. An aggressive case of a thoracic undifferentiated smarca4-deficient tumor with extensive pleural involvement.
    Hanona PF; Ezekwudo D; Fullmer J; Allen T; Jaiyesimi I
    Thorac Cancer; 2024 Apr; 15(10):847-851. PubMed ID: 38390699
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Thoracic smarca4-deficient tumors: a clinicopathological analysis of 52 cases with smarca4-deficient non-small cell lung cancer and 20 cases with thoracic smarca4-deficient undifferentiated tumor.
    Zhou P; Fu Y; Tang Y; Jiang L; Wang W
    PeerJ; 2024; 12():e16923. PubMed ID: 38374950
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Thoracic smarca4-deficient undifferentiated tumor: A clinicopathological and prognostic analysis of 35 cases and immunotherapy efficacy.
    Zhou P; Fu Y; Tang Y; Jiang L; Wang W
    Lung Cancer; 2024 Mar; 189():107471. PubMed ID: 38306886
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. [Cytopathological characteristics of smarca4-deficient thoracic undifferentiated tumors in serous effusion].
    Wang WN; Liu XT; Liang YM
    Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
    [No Abstract]    [Full Text] [Related]  

  • 10. [Clinicopathological features of smarca4-deficient lung adenocarcinoma: a study of 42 cases].
    Han J; Gao XZ; Xu Y; Liu EJ; Du Q; Chen K; Li SL
    Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):136-142. PubMed ID: 38281780
    [No Abstract]    [Full Text] [Related]  

  • 11. An in-silico analysis reveals further evidence of an aggressive subset of lung carcinoids sharing molecular features of high-grade neuroendocrine neoplasms.
    Pelosi G; Melocchi V; Dama E; Hofman P; De Luca M; Albini A; Gemelli M; Ricotta R; Papotti M; La Rosa S; Uccella S; Harari S; Sonzogni A; Asiedu MK; Wigle DA; Bianchi F
    Exp Mol Pathol; 2024 Feb; 135():104882. PubMed ID: 38237798
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. USP22 overexpression fails to augment tumor formation in MMTV-ERBB2 mice but loss of function impacts MMTV promoter activity.
    Kuang X; Salinger A; Benavides F; Muller WJ; Dent SYR; Koutelou E
    PLoS One; 2024; 19(1):e0290837. PubMed ID: 38236941
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. PROTACs Targeting BRM (SMARCA2) Afford Selective
    Berlin M; Cantley J; Bookbinder M; Bortolon E; Broccatelli F; Cadelina G; Chan EW; Chen H; Chen X; Cheng Y; Cheung TK; Davenport K; DiNicola D; Gordon D; Hamman BD; Harbin A; Haskell R; He M; Hole AJ; Januario T; Kerry PS; Koenig SG; Li L; Merchant M; Pérez-Dorado I; Pizzano J; Quinn C; Rose CM; Rousseau E; Soto L; Staben LR; Sun H; Tian Q; Wang J; Wang W; Ye CS; Ye X; Zhang P; Zhou Y; Yauch R; Dragovich PS
    J Med Chem; 2024 Jan; 67(2):1262-1313. PubMed ID: 38180485
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Molecular and Pathologic Characterization of YAP1-Expressing Small Cell lung cancer Cell Lines Leads to Reclassification as smarca4-Deficient Malignancies.
    Ng J; Cai L; Girard L; Prall OWJ; Rajan N; Khoo C; Batrouney A; Byrne DJ; Boyd DK; Kersbergen AJ; Christie M; Minna JD; Burr ML; Sutherland KD
    Clin Cancer Res; 2024 May; 30(9):1846-1858. PubMed ID: 38180245
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinoma.
    Burns L; Tukachinsky H; Raskina K; Huang RSP; Schrock AB; Sands J; Kulke MH; Oxnard GR; Tapan U
    Lung Cancer; 2024 Feb; 188():107454. PubMed ID: 38159439
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Thoracic smarca4-deficient undifferentiated tumor: current knowledge and future perspectives.
    Shinno Y; Ohe Y;
    Jpn J Clin Oncol; 2024 Mar; 54(3):265-270. PubMed ID: 38117955
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. The SWI/SNF Complex: A Frequently Mutated Chromatin Remodeling Complex in cancer.
    Nguyen VT; Tessema M; Weissman BE
    Cancer Treat Res; 2023; 190():211-244. PubMed ID: 38113003
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. [Evaluation of Efficacy and Prognosis Analysis of Stage III-IV smarca4-deficient 
Non-small Cell lung cancer Treated by PD-1 Immune Checkpoint Inhibitors plus 
Chemotherapy and Chemotherapy].
    Wang X; Tu M; Jia H; Liu H; Wang Y; Wang Y; Jiang N; Lu C; Zhang G
    Zhongguo Fei Ai Za Zhi; 2023 Sep; 26(9):659-668. PubMed ID: 37985152
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. The impact of genomic context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review.
    Fulton-Ward T; Middleton G
    Ann Oncol; 2023 Dec; 34(12):1113-1130. PubMed ID: 37875224
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Prognostic and predictive impact of molecular tumor burden index in non-small cell lung cancer patients.
    Yang F; Tang M; Cui L; Bai J; Yu J; Gao J; Nie X; Li X; Xia X; Yi X; Zhang P; Li L
    Thorac Cancer; 2023 Nov; 14(31):3097-3107. PubMed ID: 37724484
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 12.